AC Immune SAのIPO年
AC Immune SAのIPO年は何ですか。
AC Immune SAのIPO年は2016です。
IPO年の定義は何ですか。
新規公開株 (IPO)は、企業の株式を通常は機関投資家に販売し、順番に証券取引所で一般市民に販売する株式公開の一種です。
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
NASDAQのセクタHealth CareにおけるIPO年の企業と比べるAC Immune SA
AC Immune SAは何をしますか。
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
AC Immune SAと類似のipo年
- The Toronto-Dominion Bank PFD SER 9 3.7%のIPO年は2015です。
- Fura GemsのIPO年は2015です。
- Hostess BrandsのIPO年は2015です。
- Nabriva Therapeutics PlcのIPO年は2015です。
- REFのIPO年は2015です。
- H-SourceのIPO年は2015です。
- AC Immune SAのIPO年は2016です。
- American Pacific BoratesのIPO年は2017です。
- RazerのIPO年は2017です。
- DEAG Deutsche Entertainment AktiengesellschaftのIPO年は2017です。
- Hamilton Beach Brands CoのIPO年は2017です。
- Artelo BiosciencesのIPO年は2017です。
- VARTA AGのIPO年は2017です。